Publications by authors named "Carsten Siegert"

Claim this Profile
T
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.
Klaus G Parhofer, David Pittrow, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Carsten Siegert

Clin Res Cardiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.
Klaus G Parhofer, David Pittrow, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Carsten Siegert

Acta Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
Ulrich Laufs, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Carsten Siegert

Cardiovasc Drugs Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis